Tag Archives: Federal Circuit

Prometheus v. Mayo and Classen v. Biogen Sent Back to Federal Circuit

Posted on June 29, 2010 by Warren Woessner

  Not unexpectedly, today the Supreme Court granted cert. in Prometheus v. Mayo, (09-490) vacated, and remanded to the Fed. Cir. for reconsideration in view of Bilski v. Kappos, decided yesterday. While this clears the Court’s collective desk, I don’t … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

CANCELLATION OF WARF STEM CELL CLAIMS: THE “DR. HYDE” SIDE OF KSR

Posted on May 25, 2010 by Warren Woessner

Recently, in a notably unremarked decision, the Board reversed the Examiner, effectively canceling all of the claims to pluripotent human embryonic stem cells (ES) in Thomson (U.S. Pat. No. 7029913): The Foundation for Taxpayer & Consumer Rights v. Patent of Wisconsin Alumni … Continue reading →

Posted in Obviousness | Tagged , , , | Leave a comment

Therasense To Be Re-Heard En Banc – “I Feel Your Pain”

Posted on April 28, 2010 by Warren Woessner

Monday’s decision by the Federal Circuit to vacate the split panel decision in Therasense, Inc. v. Becton Dickinson & Co., 593 F.3d 1289 (Fed. Cir. 2010) (link at end of post) and rehear the case en banc makes it impossible for … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , | Leave a comment

Patenting Genes – The Conversation Myriad Needs To Start

Posted on April 5, 2010 by Warren Woessner

I watched “60 Minutes” last night, during which Kevin Noonan got about 30 seconds to justify “patenting genes” and the Myriad BRAC1-2 assays. He did as well as could be done, speaking about the good the patent system does in … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment